12.69
0.05 (0.40%)
| Previous Close | 12.64 |
| Open | 12.64 |
| Volume | 1,694,691 |
| Avg. Volume (3M) | 2,320,288 |
| Market Cap | 1,641,931,136 |
| Price / Earnings (Forward) | 222.22 |
| Price / Sales | 1.68 |
| Price / Book | 1.48 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | -11.54% |
| Operating Margin (TTM) | -16.56% |
| Diluted EPS (TTM) | -0.610 |
| Quarterly Revenue Growth (YOY) | 7.50% |
| Total Debt/Equity (MRQ) | 68.08% |
| Current Ratio (MRQ) | 2.05 |
| Operating Cash Flow (TTM) | 7.61 M |
| Levered Free Cash Flow (TTM) | -2.21 M |
| Return on Assets (TTM) | -2.75% |
| Return on Equity (TTM) | -8.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | NeoGenomics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -4.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Average | -0.20 |
|
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 1.19% |
| % Held by Institutions | 98.21% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (Needham, 18.20%) | Buy |
| Median | 14.00 (10.32%) | |
| Low | 13.00 (Piper Sandler, 2.44%) | Buy |
| Average | 14.00 (10.32%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 10.55 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 24 Feb 2026 | 13.00 (2.44%) | Buy | 9.65 |
| Needham | 17 Feb 2026 | 15.00 (18.20%) | Buy | 11.44 |
| 12 Jan 2026 | 14.00 (10.32%) | Buy | 12.49 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Jan 2026 | Announcement | NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 |
| 12 Jan 2026 | Announcement | NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue |
| 05 Jan 2026 | Announcement | NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 30 Dec 2025 | Announcement | NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors |
| 15 Dec 2025 | Announcement | NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation |
| 10 Dec 2025 | Announcement | NeoGenomics to Present New ctDNA Research at SABCS 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |